Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antibodies in cancer immunotherapy.
Karyampudi L, Knutson KL. Karyampudi L, et al. Among authors: knutson kl. Cancer Biomark. 2010;6(5-6):291-305. doi: 10.3233/CBM-2009-0141. Cancer Biomark. 2010. PMID: 20938089 Review.
Immunity and immune suppression in human ovarian cancer.
Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Preston CC, et al. Among authors: knutson kl. Immunotherapy. 2011 Apr;3(4):539-56. doi: 10.2217/imt.11.20. Immunotherapy. 2011. PMID: 21463194 Free PMC article.
Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model.
Qiu Y, Li Z, Pouzoulet F, Vishnu P, Copland JA 3rd, Knutson KL, Soussain C, Tun HW. Qiu Y, et al. Among authors: knutson kl. Br J Haematol. 2018 Nov;183(4):674-678. doi: 10.1111/bjh.15009. Epub 2017 Oct 26. Br J Haematol. 2018. PMID: 29076134 Free article. No abstract available.
Cancer immunotherapy beyond immune checkpoint inhibitors.
Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y. Marin-Acevedo JA, et al. Among authors: knutson kl. J Hematol Oncol. 2018 Jan 12;11(1):8. doi: 10.1186/s13045-017-0552-6. J Hematol Oncol. 2018. PMID: 29329556 Free PMC article. Review.
Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials.
Chumsri S, Serie DJ, Li Z, Pogue-Geile KL, Soyano-Muller AE, Mashadi-Hossein A, Warren S, Lou Y, Colon-Otero G, Knutson KL, Perez EA, Moreno-Aspitia A, Thompson EA. Chumsri S, et al. Among authors: knutson kl. Clin Cancer Res. 2019 Jul 15;25(14):4422-4430. doi: 10.1158/1078-0432.CCR-18-2206. Epub 2019 Feb 26. Clin Cancer Res. 2019. PMID: 30808774 Free PMC article. Clinical Trial.
Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine.
Knutson KL, Block MS, Norton N, Erskine CL, Hobday TJ, Dietz AB, Padley D, Gustafson MP, Puglisi-Knutson D, Mangskau TK, Chumsri S, Dueck AC, Karyampudi L, Wilson G, Degnim AC. Knutson KL, et al. Clin Cancer Res. 2020 Mar 1;26(5):1045-1053. doi: 10.1158/1078-0432.CCR-19-2123. Epub 2019 Nov 22. Clin Cancer Res. 2020. PMID: 31757875 Free PMC article. Clinical Trial.
280 results